-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Pharmaceutical Network Industry Dynamics" This year's September 29th, the 21st World Heart Day, this year's theme is "Love with Heart".
At present, cardiovascular disease has become a serious threat to the health of China's residents a major "killer", the National Cardiovascular Center in 2019 statistics show that China's annual cardiac death rate of up to 550,000, according to the 2019 China Cardiovascular Health and Disease Report, the number of cardiovascular disease patients in China has reached 330 million.
study showed that obesity, smoking, physical indulation, unhealthy eating habits and so on are the main factors that cause cardiovascular disease.
people need to protect heart health, healthy diet, adhere to exercise, more critical is to do a good job in the prevention and control of cardiovascular diseases.
years, China's relevant departments attach great importance to cardiovascular disease prevention and control work.
Health China Action (2019-2030) gives specific instructions for the prevention and treatment of cardiovascular diseases, and clearly promotes the "three high" co-management, to carry out overweight obesity, blood pressure and blood sugar increase, blood lipid abnormalities and other high-risk groups of disease risk assessment and intervention guidance, do a good job of hypertension, diabetes, blood lipid abnormal standardized management.
of this year, the State Health Insurance Administration issued the Guidance on establishing and improving the mechanism for the protection of basic medical insurance outpatients for workers (draft for comments) and solicited opinions from the public.
in this draft, to enhance the function of outpatient co-care protection.
, starting with high blood pressure, diabetes and other chronic outpatient diseases, and gradually bring the general outpatient medical expenses of frequent and common diseases into the scope of payment of the co-ordination fund.
drug price is a very important concern for patients with cardiovascular and cerebrovascular diseases.
because cardiovascular disease is a chronic disease, need to adhere to long-term medication, patient compliance is very important, good drug habits help regulate treatment.
for most patients, the cost of the drug is often a burden, and some patients find it difficult to stick to it.
With the expansion of drug belt procurement, the second batch of collection, the third batch of collection and other policies, the scope of collection and selection of varieties continue to increase, including some common cardiovascular drugs, such as Ebersatan hydrochlorochlorophenicol tablets, hydrochlorochloride tablets, these selected drugs in order to ensure quality at the same time, the price has been significantly reduced, will be conducive to reducing the burden of patients, while improving patient compliance.
especially after the price of some original drugs fell, not only can effectively reduce the burden of drug costs in the process of use, but also can make patients better follow the doctor's advice, do a good job of slow disease prevention and control.
recently released the "2020 National Health Insurance Drug Catalog adjustment through the form of examination of the list of declared drugs", it is not difficult to see the shadow of the "three high" drugs, many of which have just been approved for the market of innovative drugs shortlisted, it can be seen that China's "three high" patients concern.
when more good medicine into health insurance, it is expected to further reduce the "three high" patients' drug burden, improve the quality of life of patients.
industry believes that China's high blood pressure and diabetes control has achieved a lot of results.
, treatment and management remain weak in terms of screening.
, the public's lack of attention to lipid control is a major short plate of cardiovascular prevention, which requires the promotion of chronic disease management and early intervention.
in addition to treatment, there is also a need to focus on the clinical value of innovative drugs to meet the needs of patients with cardiovascular diseases.